Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression

Zheng,Zhen; Li,Xu; Li,Zhiliang; Ma,Xiaochun

doi:10.3892/etm.2013.1241

Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression

Authors:
- Zhen Zheng
- Xu Li
- Zhiliang Li
- Xiaochun Ma
View Affiliations

Affiliations: Department of Intensive Care Unit, The First Hospital, China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China
Published online on: July 31, 2013 https://doi.org/10.3892/etm.2013.1241
Pages: 929-936

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Artificial and bioartificial liver support systems (LSSs) appear to be safe and effective in the treatment of acute and acute‑on‑chronic hepatic failure (AHF and AOCHF); however, individually published studies and previous meta‑analyses have revealed inconclusive results. The aim of the present meta‑analysis was to derive a more precise estimation of the benefits and disadvantages of artificial and bioartificial LSSs for patients with AHF and AOCHF. A literature search was conducted in the PubMed, Embase, Web of Science and Chinese Biomedical (CBM) databases for publications prior to March 1, 2013. Crude relative risks (RRs) or standardized mean differences (SMDs) with 95% confidence intervals (95% CI) were calculated using either the fixed effects or random effects models. Nineteen randomized controlled trials (RCTs) were included, which comprised a total of 566 patients with AHF and 371 patients with AOCHF. The meta‑analysis showed that artificial LSS therapy significantly reduced mortality in patients with AOCHF; however, it had no apparent effect on total mortality in patients with AHF. The results also indicated that the use of bioartificial LSSs was correlated with decreased mortality in patients with AHF. A significant reduction in the bridging to liver transplantation was observed in patients with AOCHF following artificial LSS therapy; however, similar results were not observed in patients with AHF. Patients with AHF and those with AOCHF showed significant reductions in total bilirubin levels following artificial LSS therapy. There were no significantly increased risks of hepatic encephalopathy or bleeding in either the patients with AHF or AOCHF following artificial or bioartificial LSS therapies. Univariate and multivariate meta‑regression analyses confirmed that none of the factors explained the heterogeneity. The present meta‑analysis indicated that artificial LSSs reduce mortality in patients with AOCHF, while the use of bioartificial LSSs was correlated with reduced mortality in patients with AHF.

View Figures

View References

1.	Tuñón MJ, Alvarez M, Culebras JM and González-Gallego J: An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. World J Gastroenterol. 15:3086–3098. 2009.PubMed/NCBI
2.	Stadlbauer V, Krisper P, Aigner R, et al: Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care. 10:R1692006. View Article : Google Scholar : PubMed/NCBI
3.	Bernal W, Auzinger G, Dhawan A and Wendon J: Acute liver failure. Lancet. 376:190–201. 2010. View Article : Google Scholar
4.	van de Kerkhove MP, Hoekstra R, Chamuleau RA and van Gulik TM: Clinical application of bioartificial liver support systems. Ann Surg. 240:216–230. 2004.PubMed/NCBI
5.	Carpentier B, Gautier A and Legallais C: Artificial and bioartificial liver devices: present and future. Gut. 58:1690–1702. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Wang Y, Susando T, Lei X, et al: Current development of bioreactors for extracorporeal bioartificial liver (Review). Biointerphases. 5:FA116–FA131. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Pless G: Bioartificial liver support systems. Methods Mol Biol. 640:511–523. 2010. View Article : Google Scholar
8.	Millis JM and Losanoff JE: Technology insight: liver support systems. Nat Clin Pract Gastroenterol Hepatol. 2:398–405; quiz 434. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Nevens F and Laleman W: Artificial liver support devices as treatment option for liver failure. Best Pract Res Clin Gastroenterol. 26:17–26. 2012. View Article : Google Scholar : PubMed/NCBI
10.	Schilsky ML: Acute liver failure and liver assist devices. Transplant Proc. 43:879–883. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Liu JP, Gluud LL, Als-Nielsen B and Gluud C: Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev. CD0036282004.PubMed/NCBI
12.	Kjaergard LL, Liu J, Als-Nielsen B and Gluud C: Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA. 289:217–222. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Stutchfield BM, Simpson K and Wigmore SJ: Systematic review and meta-analysis of survival following extracorporeal liver support. Br J Surg. 98:623–631. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Knobloch K, Yoon U and Vogt PM: Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 39:91–92. 2011. View Article : Google Scholar : PubMed/NCBI
15.	Moher D, Schulz KF and Altman DG; CONSORT GROUP (Consolidated Standards of Reporting Trials): The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 134:657–662. 2001. View Article : Google Scholar
16.	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Zintzaras E and Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 28:123–137. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Ioannidis JP, Patsopoulos NA and Rothstein HR: Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 336:1413–1415. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Redeker AG and Yamahiro HS: Controlled trial of exchange-transfusion therapy in fulminant hepatitis. Lancet. 1:3–6. 1973. View Article : Google Scholar : PubMed/NCBI
21.	O’Grady JG, Gimson AE, O’Brien CJ, Pucknell A, Hughes RD and Williams R: Controlled trials of charcoal hemoper-fusion and prognostic factors in fulminant hepatic failure. Gastroenterology. 94:1186–1192. 1988.PubMed/NCBI
22.	Davenport A, Will EJ and Davison AM: Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl. 41:S245–S251. 1993.PubMed/NCBI
23.	Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA and Williams R: Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs. 17:657–662. 1994.PubMed/NCBI
24.	Ellis AJ, Hughes RD, Wendon JA, et al: Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 24:1446–1451. 1996. View Article : Google Scholar : PubMed/NCBI
25.	Mazariegos GV, Linden F, Kramer D, Patzer J and Fung JJ: Randomized clinical trial of the BioLogic-DT in treatment of acute hepatic failure (AHF) with advanced encephalopathy. Hepatology. 26(Suppl): 559A1997.
26.	Kramer L, Gendo A, Madl C, Mullen K, Kaminski-Russ K and Zauner C: A controlled study of the BioLogic-DT System in chronic hepatic encephalopathy. Hepatology. 28(Suppl): 401A1998.
27.	Wilkinson AH, Ash SR and Nissenson AR: Hemodiabsorption in treatment of hepatic failure. J Transpl Coord. 8:43–50. 1998.
28.	Ellis AJ, Hughes RD, Nicholl D, et al: Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DT. Int J Artif Organs. 22:27–34. 1999.PubMed/NCBI
29.	He JQ, Chen CY, Deng JT, Qi HX, Zhang XQ and Chen ZQ: Clinical study on the treatment of fatal hepatitis with artificial liver support system. Chinese Critical Care Medicine. 12(2): 105–108. 2000.(In Chinese).
30.	Mitzner SR, Stange J, Klammt S, et al: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 6:277–286. 2000. View Article : Google Scholar : PubMed/NCBI
31.	Stevens AC, Busuttil R, Hans S, et al: An interim analysis of a phase I/II prospective randomized, multicenter, controlled trial of the HepatAssist^® bioartificial liver support system for the treatment of fulminant hepatic failure. Hepatology. 34(Suppl): 299A2001.
32.	Heemann U, Treichel U, Loock J, et al: Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology. 36:949–958. 2002. View Article : Google Scholar : PubMed/NCBI
33.	Demetriou AA, Brown RS Jr, Busuttil RW, et al: Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 239:660–670. 2004. View Article : Google Scholar
34.	El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D and Koerfer R: First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J. 50:332–337. 2004.PubMed/NCBI
35.	Sen S, Davies NA, Mookerjee RP, et al: Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 10:1109–1119. 2004. View Article : Google Scholar : PubMed/NCBI
36.	Laleman W, Wilmer A, Evenepoel P, et al: Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 10:R1082006. View Article : Google Scholar
37.	Hassanein TI, Tofteng F, Brown RS Jr, et al: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 46:1853–1862. 2007. View Article : Google Scholar
38.	Kribben A, Gerken G, Haag S, et al: Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 142:782–789. 2012. View Article : Google Scholar : PubMed/NCBI
39.	Allen JW, Hassanein T and Bhatia SN: Advances in bioartificial liver devices. Hepatology. 34:447–455. 2001. View Article : Google Scholar : PubMed/NCBI
40.	Sorkine P, Ben Abraham R, Szold O, et al: Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med. 29:1332–1336. 2001. View Article : Google Scholar : PubMed/NCBI